GlassScriptPhysician profile
Jeffrey L Wampler
NPI 1437172558
$1,303.76
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $175 · 2021: $528 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $241.69 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $216.13 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $138.94 | 2019-2022 | |
| Neos Therapeutics, LP | $126.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $126.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.70 | 2019-2022 | |
| Genentech USA, INC. | $120.17 | 2019 | |
| Merck Sharp & Dohme LLC | $64.25 | 2020-2021 | |
| Sanofi Pasteur INC. | $38.25 | 2019-2020 | |
| Shire North American Group INC | $28.41 | 2019 | |
| Pfizer INC. | $22.43 | 2019 | |
| Alfasigma USA, INC. | $14.78 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $13.68 | 2019 | |
| Corium, LLC | $13.64 | 2022 | |
| Phadia US INC. | $13.36 | 2021 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wampler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.